Long-Term Treatment With Entecavir Induces Reversal of Advanced Fibrosis or Cirrhosis in Patients With Chronic Hepatitis B  Eugene R. Schiff, Samuel S. Lee, You–Chen Chao, Seung Kew Yoon, Fernando Bessone, Shun–Sheng Wu, Wieslaw Kryczka, Yoav Lurie, Adrian Gadano, George Kitis, Suzanne Beebe, Dong Xu, Hong Tang, Uchenna Iloeje  Clinical Gastroenterology and Hepatology  Volume 9, Issue 3, Pages 274-276.e1 (March 2011) DOI: 10.1016/j.cgh.2010.11.040 Copyright © 2011 AGA Institute Terms and Conditions

Figure 1 (A) Distribution of Knodell necroinflammatory scores at 3 biopsy time points taken at baseline, after 48 weeks (year 1) of entecavir therapy, and at the time of long-term biopsy (median, 6 y) among a subset of patients from the long-term histology cohort with an Ishak fibrosis score of 4 or greater at baseline (n = 10). (B) Distribution of Ishak fibrosis scores at 3 biopsy time points taken at baseline, after 48 weeks (year 1) of entecavir therapy, and at the time of long-term biopsy (median, 6 y) among a subset of patients from the long-term histology cohort with an Ishak fibrosis score of 4 or greater at baseline (n = 10). Clinical Gastroenterology and Hepatology 2011 9, 274-276.e1DOI: (10.1016/j.cgh.2010.11.040) Copyright © 2011 AGA Institute Terms and Conditions